DexCom, Inc. logo
DexCom, Inc. (DXCM)
Compare

DexCom, Inc. (DXCM) Average EV/FCF Ratio

EV/FCF Ratio

The current ev/fcf ratio for DexCom, Inc. (DXCM) is 21.72x as of Tuesday, June 9, 2026, shown against its trailing averages.

Average EV/FCF Ratio Chart

DXCM EV/FCF Ratio Averages

EV/FCF RATIO CURRENT

21.72x

EV/FCF RATIO TTM

37.62x

EV/FCF RATIO 3Y

66.97x

EV/FCF RATIO 5Y

181.74x

EV/FCF RATIO 10Y

1335.27x

EV/FCF RATIO 15Y

1225.31x

EV/FCF RATIO 20Y

1225.31x

About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

San Diego, CA
10,200 employees
Healthcare / Medical - Devices
Sector
Healthcare
Industry
Medical - Devices
CEO
Jacob Steven Leach